CN1504218A - 一种治疗肿瘤的药物组合物及其制备方法 - Google Patents
一种治疗肿瘤的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN1504218A CN1504218A CNA021533350A CN02153335A CN1504218A CN 1504218 A CN1504218 A CN 1504218A CN A021533350 A CNA021533350 A CN A021533350A CN 02153335 A CN02153335 A CN 02153335A CN 1504218 A CN1504218 A CN 1504218A
- Authority
- CN
- China
- Prior art keywords
- solution
- water
- injection
- adds
- reference substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims description 4
- 239000003814 drug Substances 0.000 title claims description 4
- 239000000203 mixture Substances 0.000 title description 3
- 241000208340 Araliaceae Species 0.000 claims abstract description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 17
- 235000008434 ginseng Nutrition 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- 239000000243 solution Substances 0.000 claims description 57
- 238000002347 injection Methods 0.000 claims description 40
- 239000007924 injection Substances 0.000 claims description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 30
- 239000013558 reference substance Substances 0.000 claims description 30
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 28
- 238000012360 testing method Methods 0.000 claims description 26
- 229960004756 ethanol Drugs 0.000 claims description 20
- 229940089161 ginsenoside Drugs 0.000 claims description 18
- 229930182494 ginsenoside Natural products 0.000 claims description 18
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 claims description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 17
- 229930015582 oxymatrine Natural products 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000000945 filler Substances 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- 238000011003 system suitability test Methods 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- LTTQKYMNTNISSZ-MWTRTKDXSA-N (2S)-(-)-kurarinone Chemical compound C1([C@H]2OC=3C(C[C@@H](CC=C(C)C)C(C)=C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1O LTTQKYMNTNISSZ-MWTRTKDXSA-N 0.000 claims description 7
- XQVFLLMCNGKXSM-UHFFFAOYSA-N kurarinone Natural products COc1cc(O)c(C(CC=C(C)C)C(=C)C)c2OC(CC(=O)c12)c3ccc(O)cc3O XQVFLLMCNGKXSM-UHFFFAOYSA-N 0.000 claims description 7
- KDADHLPROOOPIC-UHFFFAOYSA-N neokurarinol Natural products COc1cc(O)ccc1C1CC(=O)c2c(OC)cc(O)c(CC(CCC(C)(C)O)C(C)=C)c2O1 KDADHLPROOOPIC-UHFFFAOYSA-N 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 241000238370 Sepia Species 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000003610 charcoal Substances 0.000 claims description 4
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 238000003908 quality control method Methods 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000004809 thin layer chromatography Methods 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- -1 suspensoid Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims 4
- 239000000890 drug combination Substances 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 abstract description 4
- 208000000419 Chronic Hepatitis B Diseases 0.000 abstract description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 2
- 206010025323 Lymphomas Diseases 0.000 abstract description 2
- 208000002672 hepatitis B Diseases 0.000 abstract description 2
- 201000007270 liver cancer Diseases 0.000 abstract description 2
- 208000014018 liver neoplasm Diseases 0.000 abstract description 2
- 238000005728 strengthening Methods 0.000 abstract description 2
- 241000219784 Sophora Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 201000005296 lung carcinoma Diseases 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 241000700159 Rattus Species 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000001989 choleretic effect Effects 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 241001538365 Accipiter nisus Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000143687 Cantua buxifolia Species 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02153335 CN1209138C (zh) | 2002-11-29 | 2002-11-29 | 一种治疗肿瘤的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02153335 CN1209138C (zh) | 2002-11-29 | 2002-11-29 | 一种治疗肿瘤的药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1504218A true CN1504218A (zh) | 2004-06-16 |
CN1209138C CN1209138C (zh) | 2005-07-06 |
Family
ID=34235103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02153335 Expired - Lifetime CN1209138C (zh) | 2002-11-29 | 2002-11-29 | 一种治疗肿瘤的药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1209138C (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100437109C (zh) * | 2005-08-16 | 2008-11-26 | 李彦群 | 一种治疗肿瘤的注射液的质量控制方法 |
CN103105371A (zh) * | 2011-11-10 | 2013-05-15 | 长白山制药股份有限公司 | 一种药物组合物注射液的质量检测方法 |
CN103156951A (zh) * | 2013-04-11 | 2013-06-19 | 太仓市胜舟生物技术有限公司 | 一种治疗b细胞淋巴瘤的组合药物 |
CN103169807A (zh) * | 2013-04-11 | 2013-06-26 | 太仓市胜舟生物技术有限公司 | 一种中西组合药物在制药中的应用 |
CN110772557A (zh) * | 2019-12-06 | 2020-02-11 | 李东轩 | 康艾注射液在制备治疗或预防艾滋病药物中的应用 |
-
2002
- 2002-11-29 CN CN 02153335 patent/CN1209138C/zh not_active Expired - Lifetime
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100437109C (zh) * | 2005-08-16 | 2008-11-26 | 李彦群 | 一种治疗肿瘤的注射液的质量控制方法 |
CN103105371A (zh) * | 2011-11-10 | 2013-05-15 | 长白山制药股份有限公司 | 一种药物组合物注射液的质量检测方法 |
CN103105371B (zh) * | 2011-11-10 | 2015-03-18 | 长白山制药股份有限公司 | 一种药物组合物注射液的质量检测方法 |
CN103156951A (zh) * | 2013-04-11 | 2013-06-19 | 太仓市胜舟生物技术有限公司 | 一种治疗b细胞淋巴瘤的组合药物 |
CN103169807A (zh) * | 2013-04-11 | 2013-06-26 | 太仓市胜舟生物技术有限公司 | 一种中西组合药物在制药中的应用 |
CN110772557A (zh) * | 2019-12-06 | 2020-02-11 | 李东轩 | 康艾注射液在制备治疗或预防艾滋病药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1209138C (zh) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Iino et al. | Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis | |
CN100548323C (zh) | 一种由绞股蓝、西洋参和黄芪制成的药物组合物 | |
US20080233220A1 (en) | Further Medical Use Of A Botanical Drug Or Dietary Supplement | |
CN101856449B (zh) | 一种清热利湿,活血通淋中药组合物及制备方法和质量检测方法 | |
CN103028065B (zh) | 一种紫香益母制剂及其制备方法和检测方法 | |
CN101496870B (zh) | 一种止咳化痰的中药组合物的检测方法 | |
CN112645808A (zh) | 一种高良姜中分离的5-羟基-1,7-二苯基-3-庚酮及其应用 | |
CN110772547B (zh) | 文王一支笔提取物在制备治疗肝炎药物中的应用 | |
CN101428090B (zh) | 一种具有明确谱效关系的西藏胡黄连组合物 | |
CN100443498C (zh) | 白薇总皂苷及其皂苷化合物在抗炎药物中的应用 | |
CN1209138C (zh) | 一种治疗肿瘤的药物组合物及其制备方法 | |
CN101040906B (zh) | 一种治疗心脑血管疾病的注射剂及其制备方法和质控方法 | |
CN103816300B (zh) | 一种治疗皮肤病症或粘膜腔道病症的中药喷雾剂 | |
CN100571761C (zh) | 一种治疗肝病的中药组合物及制备方法 | |
CN1883673A (zh) | 一种复方太子参制剂及其生产方法 | |
CN107266599B (zh) | 金针菇多糖、提取方法及其在制备治疗功能性便秘药物方面的应用 | |
CN1233378C (zh) | 一种治疗口腔咽喉疾病的中药组合物及其制备方法 | |
CN103550237B (zh) | 一种茜草活性成分组合物及其在医药上的应用 | |
Zhu et al. | Total ginsenosides promote the IEC-6 cell proliferation via affecting the regulatory mechanism mediated by polyamines | |
CN104324089A (zh) | 各种成分比例稳定均一的大黄总蒽醌及其组合物用于乙型病毒性肝炎的退黄治疗 | |
CN101011543B (zh) | 一种新的抗肿瘤药物组合物 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN101391070A (zh) | 一种具有抗癌作用的中药组合物的质量控制方法 | |
CN1323682C (zh) | 一种用于小儿外感发热的中药制剂及其制备工艺 | |
CN1241610C (zh) | 一种防治前列腺炎及前列腺增生的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHANGBAISHAN PHARMACY CO., LTD. Free format text: FORMER OWNER: LI YANQUN Effective date: 20090612 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090612 Address after: No. 43 Changan Road, democratic Street, Jilin, Jiaohe Patentee after: CHANGBAISHAN PHARMACEUTICAL Co.,Ltd. Address before: No. 106, Shenzhen street, hi tech Development Zone, Jilin, Jilin Patentee before: Li Yanqun |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191218 Address after: 132000 3-1-17, purple garden, camp, Jilin, Jilin Patentee after: Li Dongxuan Address before: 43 No. 132500 Changan Road, democratic Street, Jilin, Jiaohe Patentee before: CHANGBAISHAN PHARMACEUTICAL Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20050706 |
|
CX01 | Expiry of patent term |